Home World News FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer World News FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer By Ogkologos - January 29, 2026 417 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRITON3 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR New on NCI’s Websites for December 2021 December 29, 2021 Amid Coronavirus Outbreak and Panic Buying, Stores Introduce Special Shopping Times... March 18, 2020 PARP Inhibitors Show Promise as Initial Treatment for Ovarian Cancer October 29, 2019 Molecular Analysis for Precision Oncology Congress 2022, 14-16 October 2022, Amsterdam,... September 29, 2022 Load more HOT NEWS It’s a fair COP: Why our chief clinician went to a... SBRT Emerging as an Important Treatment for Early-Stage Kidney Cancer 如何在肺癌患病期间和之后维持性健康 FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head...
